|
Thu, 03/10/2022 - 09:00 |
Grifols XEMBIFY receives European approvals, expanding access to innovative therapies |
|
Wed, 03/02/2022 - 11:14 |
Grifols partners with Feeding America to help address hunger in the U.S. |
|
Thu, 02/24/2022 - 16:27 |
Grifols signs global collaboration agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis |
|
Tue, 01/18/2022 - 15:40 |
Grifols Egypt begins taking plasma donations |
|
Tue, 01/04/2022 - 05:46 |
Grifols acquires its first plasma donation center in Canada |
|
Thu, 12/02/2021 - 00:25 |
Grifols receives first certifications for new In Vitro Diagnostics Medical Devices European Regulation |
|
Mon, 11/29/2021 - 20:16 |
Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma |
|
Tue, 11/23/2021 - 22:08 |
Grifols launches new home-care treatment service for patients with alpha-1 antitrypsin deficiency in Spain |
|
Wed, 11/17/2021 - 14:44 |
Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion |
|
Mon, 11/15/2021 - 00:45 |
Grifols is included on the Dow Jones Sustainability World Index |
|
Tue, 10/26/2021 - 02:58 |
Grifols earns approval for the voluntary public tender offer of Biotest and advances its strategy to increase the availability of plasma-derived medicines |
|
Mon, 10/18/2021 - 23:31 |
Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines |
|
Tue, 10/05/2021 - 06:36 |
Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest |
|
Thu, 09/30/2021 - 16:10 |
GigaGen Licenses ProteoNics 2G UNic Technology Platform for High Yield Production of GigaGens Mono- and Polyclonal Antibody Drug Candidates |
|
Tue, 09/28/2021 - 04:01 |
Grifols begins commercializing TAVLESSE in France, Italy and Spain to treat chronic immune thrombocytopenia |
|
Mon, 09/27/2021 - 11:39 |
Grifols earns its first Fitch corporate rating with a BB- and stable outlook |
|
Mon, 08/16/2021 - 06:36 |
Grifols advances on its strategic investment from GIC with 90% of consents from its notes holders and lenders |
|
Wed, 08/11/2021 - 07:25 |
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19 |
|
Fri, 07/30/2021 - 08:39 |
Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan |
|
Wed, 07/28/2021 - 08:54 |
Alkahest Strengthens Management Team with Addition of Cesar Cerezo as Chief Medical Officer |
|
Tue, 07/20/2021 - 11:10 |
Grifols endorses its commitment to a responsible business model and support of the 2030 Agenda for Sustainable Development by formally joining the United Nations Global Compact |
|
Mon, 07/19/2021 - 16:08 |
Grifols further expands its activity in Africa with agreement to set up an intravenous solutions manufacturing plant in Nigeria |
|
Tue, 07/13/2021 - 22:02 |
GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564 |
|
Tue, 07/13/2021 - 19:27 |
Grifols becomes official partner of UEFA Womens Football |
|
Wed, 06/30/2021 - 10:28 |
Grifols announces a strategic investment from GIC of USD 1 billion |
|
Fri, 06/25/2021 - 18:28 |
Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2020 |
|
Thu, 06/10/2021 - 11:30 |
Grifols signs Power Purchase Agreement with RWE to meet 28% of its national electricity needs using solar energy |
|
Thu, 06/03/2021 - 09:38 |
Grifols to provide Korean Red Cross with Procleix Panther for blood screening, extending donor testing leadership in Asia |
|
Tue, 05/25/2021 - 09:44 |
GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies |
|
Wed, 05/19/2021 - 18:05 |
Grifols takes another step in the fight against Alzheimers, partners with Ace to open first AMBAR Center in Barcelona |
|
Wed, 05/19/2021 - 11:00 |
Grifols takes another step in the fight against Alzheimers, partners with Ace to open first AMBAR Center in Barcelona |
|
Thu, 04/15/2021 - 14:07 |
GigaGen Publishes Research on Companys Recombinant Hyperimmunes in Nature Biotechnology |
|
Thu, 04/15/2021 - 13:39 |
Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030 |
|
Wed, 04/07/2021 - 14:46 |
Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S. |
|
Thu, 04/01/2021 - 23:16 |
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19 |
|
Thu, 03/25/2021 - 10:01 |
Grifols Procleix UltrioPlex E and Procleix Babesia assays receive CE mark |
|
Mon, 03/22/2021 - 22:35 |
GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting |
|
Mon, 03/22/2021 - 09:32 |
Grifols installs first-ever DG Reader Net analyzer in North America |
|
Thu, 03/18/2021 - 08:28 |
Grifols launches patient point-of-care system for monitoring infliximab in Europe |
|
Tue, 03/09/2021 - 19:19 |
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins |
|
Mon, 03/08/2021 - 07:31 |
Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimers and Parkinsons Disease |
|
Wed, 01/27/2021 - 05:21 |
Grifols is included in the Bloomberg Gender-Equality Index for its commitment to gender equality |
|
Mon, 01/18/2021 - 07:01 |
Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19 |
|
Tue, 12/15/2020 - 21:51 |
Grifols creates a Sustainability Committee to strengthen its long-term sustainable growth model |
|
Tue, 12/08/2020 - 21:17 |
Grifols is included on Euronext Vigeo indices and recognized once again as one of the world's most sustainable companies |
|
Tue, 11/24/2020 - 16:45 |
Strategic alliance between Grifols and the Egyptian government to boost plasma-derived medicines self-sufficiency in the Middle East and Africa |
|
Mon, 11/16/2020 - 15:21 |
The Dow Jones Sustainability Index recognizes Grifols as one of the worlds most sustainable companies |
|
Mon, 11/16/2020 - 06:53 |
B. Braun Melsungen AG and Grifols form strategic alliance to offer integrated solutions for safe automated drug preparation and administration |
|
Thu, 11/12/2020 - 11:34 |
Grifols partners with TRC Healthcare to streamline intravenous compounding education |
|
Mon, 11/09/2020 - 09:25 |
Grifols consolidates its Hospital Division as a reference in innovative solutions with the acquisition of the 49% stake in MedKeeper |
|
Mon, 10/19/2020 - 18:42 |
MAJOR HOLDERS AND TREASURY STOCK |
|
Fri, 10/09/2020 - 05:14 |
Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19 |
|
Thu, 10/01/2020 - 11:02 |
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S. |
|
Mon, 09/07/2020 - 13:40 |
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome |
|
Tue, 07/28/2020 - 12:57 |
COVID-19 Plasma Therapies in Clinical Trials |
|
Tue, 07/28/2020 - 10:04 |
Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials |
|
Mon, 07/27/2020 - 10:11 |
Results of Grifols AMBAR clinical trial published in Alzheimer's & Dementia: The Journal of the Alzheimers Association |
|
Thu, 07/23/2020 - 10:46 |
Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products |
|
Mon, 07/20/2020 - 11:01 |
Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million |
|
Thu, 07/09/2020 - 08:00 |
Grifols starts commercializing TAVLESSE in Europe, diversifying its medicines portfolio |
|
Fri, 06/26/2020 - 08:09 |
Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2019 |
|
Wed, 06/17/2020 - 10:50 |
Increase the awareness of hemophilia and access to its diagnosis. |
|
Thu, 06/11/2020 - 04:26 |
Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19 |
|
Wed, 06/10/2020 - 06:57 |
Grifols and Hologic embark on a unique collaboration for COVID-19 testing in Spain |
|
Fri, 05/29/2020 - 11:16 |
Grifols acquires parcel in Llica de Vall to grow the companys production facilities |
|
Thu, 05/07/2020 - 11:40 |
Grifols reinforces its liquidity position to EUR 1,700 million |
|
Fri, 03/27/2020 - 14:06 |
Grifols and Shanghai RAAS close their strategic alliance in China |
|
Wed, 02/12/2020 - 18:58 |
Grifols PharmacyKeeper ranked No. 1 in KLAS rating, extends category leadership |
|
Thu, 12/12/2019 - 10:28 |
Grifols launches XEMBIFY (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment |
|
Fri, 12/06/2019 - 16:15 |
Grifols presents its latest Alzheimers clinical trial data |
|
Thu, 12/05/2019 - 10:17 |
Grifols streamlines hospital pharmacy operations with new KIRO Fill technology and PharmacyKeeper enhancements |
|
Wed, 12/04/2019 - 09:27 |
Grifols introduces its first plasma protein-based biosurgery product |
|
Tue, 10/29/2019 - 05:28 |
Grifols increases its revenues by 14.5% to EUR 3,738 million |
|
Fri, 09/06/2019 - 18:00 |
Grifols and Mondragon sign technology collaboration agreement |
|
Tue, 07/16/2019 - 01:13 |
Grifols presents additional encouraging Alzheimers trial results at AAIC |
|
Thu, 07/04/2019 - 13:30 |
Grifols announces FDA approval of Xembify , 20% subcutaneous immunoglobulin for primary immunodeficiencies |
|
Wed, 06/19/2019 - 10:14 |
Grifols to launch plasma-protein-based bleeding-control solutions |
|
Fri, 05/24/2019 - 02:33 |
Grifols reinforces its long-term and sustainable growth strategy with EUR 1,400 million in capital investments in 2018-2022 |
|
Wed, 05/22/2019 - 21:23 |
Grifols publishes its 2018 Corporate Responsibility Report as part of its commitment to transparency |
|
Tue, 05/07/2019 - 08:35 |
Grifols reports 13% revenue growth to EUR 1,157 million and confirms its solid operational performance |
|
Tue, 04/30/2019 - 04:38 |
Grifols Announces PharmacyKeeper Bidirectional Integration with Epic |
|
Thu, 04/18/2019 - 08:39 |
Grifols US donor centers exceed 250,000 pounds of food collected |
|
Mon, 04/15/2019 - 06:42 |
Grifols donations of blood clotting factor helping people with hemophilia globally |
|
Fri, 03/29/2019 - 13:46 |
Grifols presents new data to support the effectiveness of its clinical trial to treat Alzheimer's |
|
Thu, 03/07/2019 - 08:17 |
Grifols enters a strategic alliance with Shanghai RAAS to boost growth of its plasma-derived products and diagnostic solutions in China |
|
Thu, 02/21/2019 - 08:13 |
Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year |
|
Thu, 02/07/2019 - 02:20 |
Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System |
|
Wed, 01/23/2019 - 04:13 |
Grifols Announces Collaboration and License Agreement with Rigel Pharmaceuticals |
|
Tue, 01/08/2019 - 16:33 |
Grifols receives FDA approval of Erytra Eflexis , the latest advancement in scalable blood typing solutions |
|
Wed, 12/19/2018 - 04:11 |
Grifols partners with the Republic of Liberia to explore an innovative approach to combat Ebola virus disease |
|
Thu, 11/15/2018 - 12:17 |
Grifols lanza en Espana AlfaCare, el primer programa de soporte a pacientes con Deficit de Alfa-1 Antitripsina (DAAT) |
|
Sat, 10/27/2018 - 04:49 |
Grifols AMBAR results demonstrate a significant reduction in the progression of moderate Alzheimer's Disease |
|
Mon, 10/22/2018 - 02:05 |
Grifols invests in ultrahigh sensitive disease diagnostic and prognostic technology |
|
Thu, 10/11/2018 - 19:53 |
FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing |
|
Sun, 10/07/2018 - 20:22 |
Grifols Delivers Promise of Advancing Plasma-derived Medicines through Innovative Vision and Donor Support |
|
Thu, 08/16/2018 - 07:09 |
Grifols Announces Winner of the 2018 SPIN Award for Immunoglobulin Research in Neurology at the 2018 Peripheral Nerve Society Annual Meeting |
|
Tue, 08/14/2018 - 06:50 |
Procleix Zika Virus Assay Approved by the FDA for Blood Screening on the Procleix Panther System |
|
Thu, 08/02/2018 - 22:37 |
Grifols achieves key milestone with FDA approval of the new Consolidated Manufacturing Facility (CMF) for production of recombinant proteins |
|
Wed, 08/01/2018 - 05:34 |
Grifols expands its plasma collection network by acquiring 24 Biotest centers in the United States |
|
Fri, 07/27/2018 - 11:18 |
Grifols increases net profits by 15% to EUR 319 million, with sustained operational revenue growth of 7% |
